BR112023019182A2 - Uso de um inibidor de citidina desaminase na preparação de um medicamento, sistema, kit ou artigo de manufatura e composição - Google Patents

Uso de um inibidor de citidina desaminase na preparação de um medicamento, sistema, kit ou artigo de manufatura e composição

Info

Publication number
BR112023019182A2
BR112023019182A2 BR112023019182A BR112023019182A BR112023019182A2 BR 112023019182 A2 BR112023019182 A2 BR 112023019182A2 BR 112023019182 A BR112023019182 A BR 112023019182A BR 112023019182 A BR112023019182 A BR 112023019182A BR 112023019182 A2 BR112023019182 A2 BR 112023019182A2
Authority
BR
Brazil
Prior art keywords
composition
cytidine deaminase
kit
article
manufacture
Prior art date
Application number
BR112023019182A
Other languages
English (en)
Inventor
K Jha Babal
Xiaorong Gu
Yogen Saunthararajah
Original Assignee
Cleveland Clinic Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Found filed Critical Cleveland Clinic Found
Publication of BR112023019182A2 publication Critical patent/BR112023019182A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

uso de um inibidor de citidina desaminase na preparação de um medicamento, sistema, kit ou artigo de manufatura e composição. a presente invenção fornece composições, sistemas, kits e métodos para tratar um indivíduo com uma infecção por vírus de rna (por exemplo, sars-cov-2) administrando ou fornecendo uma composição que compreende um inibidor de citidina desaminase (por exemplo, tetra-hidrouridina ou cedazuridina).
BR112023019182A 2021-03-26 2022-03-22 Uso de um inibidor de citidina desaminase na preparação de um medicamento, sistema, kit ou artigo de manufatura e composição BR112023019182A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163166567P 2021-03-26 2021-03-26
PCT/US2022/021322 WO2022204126A1 (en) 2021-03-26 2022-03-22 Treatment of rna virus infection with a cytidine deaminase inhibitor

Publications (1)

Publication Number Publication Date
BR112023019182A2 true BR112023019182A2 (pt) 2023-11-28

Family

ID=83397813

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023019182A BR112023019182A2 (pt) 2021-03-26 2022-03-22 Uso de um inibidor de citidina desaminase na preparação de um medicamento, sistema, kit ou artigo de manufatura e composição

Country Status (9)

Country Link
US (1) US20240197766A1 (pt)
EP (1) EP4313069A1 (pt)
CN (1) CN117835984A (pt)
AU (1) AU2022244240A1 (pt)
BR (1) BR112023019182A2 (pt)
CA (1) CA3211943A1 (pt)
IL (1) IL307181A (pt)
MX (1) MX2023011120A (pt)
WO (1) WO2022204126A1 (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2778B1 (en) * 2007-10-16 2014-03-15 ايساي انك Certain vehicles, installations and methods
WO2017117006A1 (en) * 2015-12-29 2017-07-06 The Board Of Trustees Of The Leland Stanford Junior University Use of a dhodh inhibitor in combination with an inhibitor of pyrimidine salvage
US11959917B2 (en) * 2018-09-18 2024-04-16 Siemens Healthcare Diagnostics Inc. Methods and reagents for Zika virus immunoassays
WO2021007283A1 (en) * 2019-07-09 2021-01-14 Regents Of The University Of Minnesota Potentiation of antiviral nucleobases as rna virus therapy

Also Published As

Publication number Publication date
CN117835984A (zh) 2024-04-05
AU2022244240A1 (en) 2023-10-05
EP4313069A1 (en) 2024-02-07
CA3211943A1 (en) 2022-09-29
IL307181A (en) 2023-11-01
US20240197766A1 (en) 2024-06-20
MX2023011120A (es) 2023-10-03
WO2022204126A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
BR112022017308A2 (pt) Composição que compreende lactoferrina e cepas bacterianas probióticas para uso oral com ação antiviral
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
BRPI0306993B8 (pt) polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
BR112022002442A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BR0206614A (pt) Composto, composição farmacêutica, método para inibir a polimerase viral de rna dependente de rna e/ou inibir a replicação viral de rna dependente de rna, método para tratar uma infecção viral de rna dependente de rna, e, uso de um composto
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
BR112016026556A8 (pt) inibidores de mek, de p38 e/ou de nfkb, seus usos, composição, sistema de teste in vitro, seu uso, e método para detecção de moléculas eficazes na profilaxia e/ou tratamento de uma co-infecção
CO2022014073A2 (es) Compuestos antivirales y métodos para la administración de los mismos
BR112022022456A2 (pt) Proteínas de ligação de repetição de anquirina e seus usos
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112013002296A2 (pt) composição farmacêutica e respectivo uso e método para tratar doença infecciosa
BRPI0715396B8 (pt) método de produção de uma composição para vacina
Pila-Castellanos et al. Mitochondrial morphodynamics alteration induced by influenza virus infection as a new antiviral strategy
BR112023015937A2 (pt) Compostos, composições e métodos de uso dos mesmos
BR112019008810A2 (pt) micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer
BR112023006024A2 (pt) Terapias de imuno-oncologia com conjugados de il-2
BR112022017923A2 (pt) Tratamento de infecção por coronavírus
BR112023001129A2 (pt) Pró-fármacos antivirais, formulações farmacêuticas e métodos
BRPI0516224A (pt) produto alimentìcio contendo um ou vários microorganismos vivos e pelo menos um ingrediente alimentìcio bioativo de interesse, processo de preparação do mesmo, e, utilização de um produto alimentìcio
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
UY39313A (es) Composiciones amortiguadoras para el tratamiento de infecciones virales transmitidas por el aire
BR112023019182A2 (pt) Uso de um inibidor de citidina desaminase na preparação de um medicamento, sistema, kit ou artigo de manufatura e composição